BioLargo, Inc. filings document an operating company with cleantech, environmental engineering and life sciences subsidiaries, including disclosures tied to product and service revenue, partially owned subsidiaries, debt obligations and common stock. Registration statements and related exhibits describe common stock, capital structure, resale registration rights and equity financing arrangements.
BioLargo's Form 8-K filings record Regulation FD materials, investor presentation exhibits, annual operating-result releases, shareholder town hall transcripts, material definitive agreements and officer compensation converted into common stock. The filings also provide formal disclosure around governance, liquidity, subsidiary activity and risk factors associated with commercializing water treatment, medical technology, engineering services and energy-storage businesses.
BioLargo, Inc. (BLGO) Chief Science Officer and director Kenneth Reay Code acquired 566,261 common shares on September 30, 2026, at $0.08 per share in exchange for a reduction in amounts BioLargo owed him for salary and unreimbursed business expenses. The acquired shares are subject to a lock-up agreement restricting sale until BioLargo reports gross revenue of at least $40 million on a consolidated basis for any reported period, its market capitalization exceeds $300 million, or a change in control occurs. On the same date, Code gifted 2,000,000 common shares.
BioLargo, Inc. President Dennis P. Calvert received 931,886 shares of common stock on September 30, 2026, in exchange for reducing amounts the company owed him for salary and unreimbursed business expenses, at an acquisition price of $0.08 per share. The shares are locked up and restricted from sale until the company reports gross revenue of at least $40 million on a consolidated basis for any reported period, its market capitalization exceeds $300 million, or a change in control occurs. A limited liability company owned and controlled by Calvert also acquired 2,000,000 shares as a gift; reported beneficial ownership following that transaction includes 3,528,695 shares held indirectly through the company.
BioLargo, Inc. director Dennis E. Marshall acquired two options on September 30, 2026. One covers 281,248 shares and replaced an option for 29,605 shares that expired unexercised; the other covers 234,375 shares and was issued as payment for $18,750 in board fees for the most recently completed quarterly period. Both options have an $0.08 exercise price and expire September 30, 2036.
BioLargo, Inc. (BLGO) director Jack B. Strommen received an option to purchase 187,500 common shares on September 30, 2026, with an exercise price of $0.08 per share. The option was issued as payment for $15,000 in fees due for board service during the most recently completed quarterly period under the company's 2024 Equity Incentive Plan. The reported post-transaction share position was 2,771,762 shares, and the option expires September 30, 2036.
BioLargo, Inc. director Christina Elaine Bray acquired an option to purchase 234,375 common shares on September 30, 2026, at an exercise price of $0.0800 per share, expiring September 30, 2036. The option was issued for $18,750 in fees due for board service during the most recently completed quarterly period under BioLargo’s 2024 Equity Incentive Plan. Following the grant, Bray’s reported direct options covered 1,781,075 shares.
BioLargo, Inc. (BLGO) director Linda Park acquired an option award covering 234,375 common shares on September 30, 2026, with an exercise price of $0.08 per share. The option was issued for $18,750 in fees due for board service during the most recently completed quarterly period, under BioLargo’s 2024 Equity Incentive Plan.
BioLargo, Inc. (BLGO) filed an amendment to provide the full transcript of a September 10, 2026 shareholder town hall and business update. Management described a portfolio model that “manufactures companies” around proprietary technologies, including wound-care subsidiary Clyra Medical, the Cellinity battery platform, PFAS water treatment, engineering services, and a new consumer-products group and Tũ Nipi Water Solutions alliance.
Leaders highlighted that core revenue (excluding the Pooph odor-control line) has been rising quarter to quarter, supported by the engineering segment, while consolidated results were heavily impacted by the loss of Pooph and a related ~$4 million write-down. The parent company’s overhead is about $250,000 per month, with over $2 million in cash and roughly 86% of recent capital raised at the subsidiary level. Management cited indicative valuations of about $100 million for Clyra (BioLargo owns 48%) and about $33–34 million from a prior Cellinity financing, arguing that these alone exceed BLGO’s market cap. Near-term goals include launching the BioLargo CPG brand in October, converting Clyra’s new distributors and a large yet-undisclosed partner into orders, winning larger PFAS and industrial-water projects (often $5–40 million in scope), and progressing minerals and oil-sands projects with partners.
BioLargo, Inc. (BLGO) furnished an investor slide presentation in connection with a webcast investor conference held on September 10, 2026 at 1:00 PM Pacific Time. The slides are provided as Exhibit 99.1 under a Regulation FD disclosure and are expressly treated as “furnished,” not “filed,” under federal securities laws.
The company states that the information in this report and its exhibits will not be incorporated by reference into other SEC filings and that it undertakes no obligation to update the disclosed information, directing readers to the “Safe Harbor Act” discussion in the exhibit for important forward-looking statement information.
BioLargo, Inc. reported sharply weaker results for the six months ended June 30, 2026. Total revenue was $2.36 million, down from $6.05 million a year earlier, as product revenue fell to $0.99 million from $4.81 million. Service revenue grew modestly to $1.36 million.
Gross profit declined to $1.13 million from $2.91 million, while operating expenses increased to $8.06 million, resulting in an operating loss of $6.93 million versus $3.66 million. Net loss was $7.41 million, with $5.05 million attributable to common shareholders. Cash used in operations was $5.97 million. At June 30, 2026, cash was $2.19 million, total assets $6.67 million, and total liabilities $9.40 million, producing a stockholders’ deficit of $2.73 million. Management disclosed a working capital deficit of $1.27 million and stated that current gross profits are not expected to fund operations for 2026, raising substantial doubt about the company’s ability to continue as a going concern absent increased revenues or additional financing.
BIOLARGO, INC. Chief Science Officer and director Kenneth Reay Code received a grant of 532,567 shares of common stock at an acquisition price of $0.1135 per share. The shares were issued by the company in exchange for reducing amounts owed to him for salary and unreimbursed business expenses.
The new award is subject to a Lock-Up Agreement that restricts any sale until the company reports at least $40 million of gross revenue on a consolidated basis for a reported period, its market capitalization exceeds $300 million, or there is a change in control. Following this grant, Code beneficially owns 26,408,319 shares, including 22,139,012 shares held indirectly through a wholly owned corporation.